Neoadjuvant Immunochemotherapy Promising in Oral SCC : vimar

A small trial reported a 60% response rate to neoadjuvant immunochemotherapy in oral squamous cell carcinoma. The study was published as a preprint and has not yet been peer reviewed.

Related Keywords

China , , National Natural Science Foundation Of China , National Natural Science Foundation , Neoadjuvant , Squamous Carcinoma , Cancer , Alignant Neoplasia , Arcinoma , Peer Review , Tumor , Surgery , Neutropenia , Toxicology , Chemotherapy , Fellowship , Yellows , Hypokalemia , Intravenous Iv , Intravenous , Tv , Leukopenia , Physician Assistants ,